Pennsylvania Breast Cancer Coalition

Breast cancer risk dramatically reduced with osteoporosis drug

Published in Surgery Litigation and Law Weekly, May 19th, 2006

The Pennsylvania Breast Cancer Coalition (PBCC) salutes the National Surgical Adjuvant Breast and Bowel Project (NSABP) for their breakthrough discovery in the Study of Tamoxifen and Raloxifene (STAR) clinical trial, which demonstrates the success of raloxifene (Evista) in reducing breast cancer risk for postmenopausal women at increased risk of the disease with fewer side effects than tamoxifen.

Raloxifene (Evista) is currently prescribed for osteoporosis.

"These results indicate an important and significant breakthrough in our ongoing battle with breast cancer, and serve as an example of the value of clinical trials in breast cancer research and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly

Source: Surgery Litigation and Law Weekly (2006-05-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry